T. cruzi Incidence Study in Blood Donors and its Implications for One-time Testing of Blood Donors Robert Duncan, Ph.D. DETTD, CBER, FDA Blood Products.
Genotoxic Impurities
1 Panel: Governance at the Institutional and National Levels: national regulatory frameworks Barbara J. Evans, Ph.D., J.D., LL.M. Director, Center for.
The Abbreviated Donor Questionnaire Update from AABB Donor History Task Force to BPAC
Adaptive Designs for Clinical Trials Frank Bretz Novartis 24 April 2013, Tel Aviv.
Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.
Patient Reported Outcomes in Oncology Trials Virginia Kwitkowski Clinical Reviewer-- FDA Division of Drug Oncology Products Member OND Patient Reported.
1 Research Study: The Participation of Pregnant Women in Clinical Research: Implications for Practice within the U.S. Pharmaceutical Industry University.
CPTR Overview
